86.23USD-0.29%Mkt Cap: 4.75B USDP/E: —Last update: 2026-05-26
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal ant…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap4.75B USD
Enterprise Value3.79B USD
Revenue (TTM)1.34M USD
Gross Profit1.34M USD
Net Income (TTM)-162.34M USD
Revenue/Share0.0320 USD
Last Price86.23 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees92
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-19.37
PEG—
EV/EBITDA-19.82
EV/Revenue2836.71
P/S3667.47
P/B4.07
EPS (TTM)-4.23
EPS (Forward)-4.63
52W Range
16.6487% of range96.50
52W High96.50 USD
52W Low16.64 USD
Profitability
Gross Margin100.00%
Oper. Margin-10050.32%
EBITDA Margin0.00%
Profit Margin-7973.33%
ROE-32.90%
ROA-30.58%
Growth
Revenue Growth-60.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-129.06M USD
CapEx (TTM)213.00K USD
FCF Margin-5316.59%
FCF Yield-1.50%
Net Debt-1.11B USD
Net Debt/EBITDA5.81
Balance Sheet
Debt/Equity0.00
Current Ratio29.25
Quick Ratio29.06
Book Value/Sh22.01 USD
Cash/Share20.33 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)125.83 USD
Target Range98.00 USD – 200.00 USD
# Analysts12
Ownership
Shares Out.54.67M
Float54.60M
Insiders0.13%
Institutions116.04%
Short Interest
Short Ratio9.3d
Short % Float13.82%
Short % Out.12.00%
Shares Short6.55M
Short (prev mo.)9.07M
Technical
SMA 5085.89 (+0.4%)
SMA 20051.60 (+67.1%)
Beta0.09
S&P 52W Chg28.31%
Avg Vol (30d)502.46K
Avg Vol (10d)471.76K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—